Loss of a metabolic gene protects against fatty liver disease
Researchers at the University of Michigan have identified that rare loss-of-function mutations in the LYPLAL1 gene protect women against metabolic dysfunction-associated steatotic liver disease (MASLD). This discovery provides a potential new therapeutic target for treating fatty liver disease.
More than one-third of the global population has metabolic dysfunction-associated steatotic liver disease, or MASLD, a condition in which fat accumulates in the liver. MASLD can progress to more severe diseases like metabolic dysfunction-associated steatohepatitis, cirrhosis and hepatocellular carcinoma. Treatment options are limited and focus on weight loss through lifestyle changes and the use of a couple of medications, while liver transplantation is reserved for advanced disease.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in